Previous 10 |
MINNEAPOLIS, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced a proposed public offering of its common stock and warrants to purchase common stock. The offering is subject to market and ot...
MINNEAPOLIS, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc . (NASDAQ: AIPT) (“ Precision ”) today announced the effectiveness of its Form S-4 registration statement, the establishment of the date of its special meeting of stockholders in connection with the pro...
MINNEAPOLIS, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announces its Skyline Medical division, producer of the FDA-approved and CE-marked STREAMWAY ® System for...
Amyris (NASDAQ: AMRS ) +41% on $255M cannabinoid deal . More news on: Amyris, Inc., Melinta Therapeutics, Moleculin Biotech, Inc., Stocks on the move, Read more ...
MINNEAPOLIS, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announces its TumorGenesis subsidiary has identified three thyroid cancer cell types and has isolated the discovery biomarkers. Th...
MINNEAPOLIS, Jan. 25, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its Skyline Medical division, producer of the FDA-approved and CE-marked STREAMWAY® System for ...
News, Short Squeeze, Breakout and More Instantly...
Precision Therapeutics Inc. Company Name:
AIPT Stock Symbol:
NASDAQ Market:
MINNEAPOLIS, June 12, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: AIPT) (“Predictive Oncology” or the “Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today it has appointed Am...
MINNEAPOLIS, June 11, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (Nasdaq: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that it has changed its co...
The global precision medicine market is expected to reach revenues of over $216.75 billion by 2028, propelled by a growing interest in personalized approaches to disease treatments and the application of new technologies Precision Therapeutics and its three wholly owned subdivisions are a...